Immunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in advanced adrenocortical carcinoma (ACC). This editorial focus on the possible mechanisms of ACC immunoevasion and suggests strategies to overcome the intrinsic immunotherapy resistance of this disease.

Immunotherapy failure in adrenocortical cancer: Where next?

Perotti P.;
2018

Abstract

Immunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in advanced adrenocortical carcinoma (ACC). This editorial focus on the possible mechanisms of ACC immunoevasion and suggests strategies to overcome the intrinsic immunotherapy resistance of this disease.
7
12
E5
E8
Cosentini D.; Grisanti S.; Volta A.D.; Lagana M.; Fiorentini C.; Perotti P.; Sigala S.; Berruti A.
File in questo prodotto:
File Dimensione Formato  
Immunotherapy failure in adrenocortical cancer_ where next_.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 468.12 kB
Formato Adobe PDF
468.12 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1795065
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 29
social impact